Strides Pharma Science Ltd (STAR) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Strides Pharma Science Ltd on NSE and BSE, with an AI summary of each filing.
Transcript of Earnings Call pertaining of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026
Transcript · 02 Nov 2026, 10:09 pm
Audio Recording of Earnings Call pertaining to unaudited Financial Results for the quarter and half year ended September 30, 2026
Audio / Video · 30 Oct 2026, 6:41 pm
Strides Pharma Releases Audio Recording for Q2 & H1 FY27 Earnings Call Strides Pharma Science has made available the audio recording of its earnings conference call held on 30th Oct'26 at 10:00 hrs IST. The call discussed the company's unaudited financial results for the quarter and half-year ended 30th Sep'26. The recording is accessible to investors and analysts on the company’s official website under the quarterly results section, compliant with SEBI listing regulations.
Appointment of Mr. Biren Gabhawala (DIN:03091772) as a Non-Executive Independent Director of the Company with effect from November 1, 2026.
Change in Management · 30 Oct 2026, 12:33 am
Strides Pharma Appoints Biren Gabhawala as Non-Executive Independent Director Strides Pharma Science Limited's Board approved the appointment of Mr. Biren Gabhawala as a Non-Executive Independent Director for a five-year term starting 1st Nov'26, subject to shareholder approval. The move is part of the company's planned Board succession planning initiative. Gabhawala, a Chartered Accountant and Senior Partner at C.M. Gabhawala & Co. with over 30 years of experience, previously served as Independent Director and Audit Committee Chair at eClerx Services and 3M India, strengthening the company's financial oversight and governance capabilities.
Allotment of Equity shares pursuant to exercise of Stock Options.
Others (Uncategorized) · 30 Oct 2026, 12:30 am
Strides Pharma Science Allots 7,500 Equity Shares Under ESOP 2016 Strides Pharma Science approved the allotment of 7,500 equity shares of face value Rs. 10 each on 29th Oct'26, pursuant to the exercise of stock options under the Strides ESOP 2016 Plan. The new shares rank pari passu with existing equity shares. Consequently, the company's paid-up equity share capital increased from Rs. 921,727,140 (92,172,714 shares) to Rs. 921,802,140 comprising 92,180,214 equity shares of Rs. 10 each.
Earnings presentation for the quarter and half year ended September 30, 2026.
Investor Presentation · 30 Oct 2026, 12:27 am
Strides Pharma Reports Q2FY27 Results with Ex-US Revenue Surpassing US Business Strides Pharma Science posted Q2FY27 revenue of ₹14,297m, up 17.1% YoY, driven by Ex-US markets growing 31% YoY to ₹6,963m and surpassing US revenue (₹6,855m, up 9% YoY) for the first time. EBITDA rose 8.4% YoY to ₹2,509m with margins at 17.6% (-140 bps YoY) due to higher material and logistics costs. Operational PAT grew 11.5% YoY to ₹1,358m. Net debt increased by ₹2,114m in H1FY27 to ₹16,479m (1.72x EBITDA). Strides shifted its ~$375m US revenue goal beyond FY28 amid normalized oral solid opportunities and controlled substance quota constraints.
Strides Delivers Strong Performance with Q2FY27 Revenue at Rs. 14.297m, Grew 17% YoY. Ex-US Markets Up 31% YoY; EBITDA Up 8% YoY to Rs. 2,509m, Crossing Rs. 2,500m in a Quarter for the First Time.
Press Release · 30 Oct 2026, 12:24 am
Strides Pharma Reports Robust Q2FY27 Results Led by Ex-US Growth Strides Pharma Science posted a 17.1% YoY revenue growth to ₹14,297m for Q2FY27 ended 30th Sep'26, driven by Ex-US markets surging 31.0% YoY to ₹6,963m and surpassing US revenue of ₹6,855m (up 9.0% YoY). EBITDA rose 8.4% YoY to a record ₹2,509m, despite margins contracting 140 bps YoY to 17.6% due to freight and raw material pressures. Operational PAT increased 11.5% YoY to ₹1,358m, while reported PAT reached ₹1,341m. H1 net debt rose ₹2,114m amid higher inventory holding.
Financial Results for the quarter and half year ended Sept 30, 2026
Financial Result · 30 Oct 2026, 12:14 am
Strides Pharma Science Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 30 Oct 2026, 12:13 am
Strides Pharma Science Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 14,297 (+17.1% YoY | +13.0% QoQ) ■ EBITDA: 2,509 (+8.4% YoY | +9.2% QoQ) ■ EBITDA Margin (%): 17.5 (-142 bps YoY | -61 bps QoQ) ■ PAT: 1,308 (+2.6% YoY | -16.6% QoQ) ■ EPS (INR): 14.2 (+2.5% YoY | -16.6% QoQ)
Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026
Intimation · 30 Oct 2026, 10:00 am
Strides Pharma Schedules Q2FY27 Earnings Conference Call for 30th Oct'26 Strides Pharma Science Limited will host an earnings conference call for investors and analysts on 30th Oct'26 at 10:00 AM IST to discuss its unaudited financial results for the quarter and half-year ended 30th Sep'26 (Q2FY27). Key management participants include Managing Director & Group CEO Badree Komandur and Group CFO Vikesh Kumar. Dial-in access is available across major regions, including India, the US, the UK, Singapore, and Hong Kong.
Strides Pharma Science Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 29 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 29 Oct 2026, 5:30 am
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve This is to inform you ....
Intimation · 29 Oct 2026, 5:30 am
Strides Pharma Science Schedules Board Meeting to Approve Q2 Results Strides Pharma Science Limited has scheduled a Board of Directors meeting on 29th Oct'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for designated persons has been closed from 1st Oct'26 and will reopen 48 hours after the formal declaration of the financial results.
Strides'' Sustainability Report for FY26
Others (Uncategorized) · 23 Sept 2026, 10:02 pm
Completion of USFDA Inspection at the Company''s Formulation Facility at Alathur
Others (Uncategorized) · 12 Sept 2026, 3:17 am
Strides Pharma Receives USFDA Form 483 With Three Observations for Alathur Facility The USFDA concluded a routine cGMP inspection at Strides Pharma Science's formulations facility in Alathur, Chennai, conducted from 2nd Sep'26 to 11th Sep'26. Upon completion of the inspection, the regulator issued a Form 483 containing three observations. The company confirmed it will submit its response to the USFDA within the stipulated timeframe.
Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in Bengaluru
Press Release · 20 Aug 2026, 1:07 am
Strides Receives USFDA EIR for Flagship Bengaluru Facility Strides Pharma Science received an Establishment Inspection Report (EIR) on 19 Aug'26 for its flagship Bengaluru facility, indicating successful closure of a USFDA inspection. The cGMP inspection, conducted from 12 May'26 to 20 May'26, had initially resulted in a Form 483 with five observations. The USFDA has now classified the inspection outcome as Voluntary Action Indicated (VAI), a positive regulatory development. This facility manufactures tablets, capsules, and oral liquids for regulated and international markets, supporting current and future products.
Voting results along with Scrutinizers report for 35th AGM.
Annual General Meeting · 18 Aug 2026, 9:31 pm
Proceedings of 35th Annual General Meeting of the Company
Annual General Meeting · 14 Aug 2026, 10:38 pm
Transcript of Earnings Call pertaining to Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
Transcript · 03 Aug 2026, 10:54 pm
Strides Pharma Q1 FY27: Ex-US Growth Cushions Stable US Performance Strides Pharma reported steady Q1 FY27 results, with revenue up 13% YoY driven by strong Ex-US markets growth of 17% YoY to ₹5,875m. US revenue was stable at ₹6,282m ($68m). EBITDA margin held at 18.2%, absorbing ₹131m in geopolitical costs. Reported PAT grew 56.7% YoY to ₹165.5 crore, boosted by a one-time gain. Gross margin expanded 60 bps YoY to 60.9%. Net debt decreased to ₹1,424.6 crore, with Net Debt-to-EBITDA at 1.52x. Management reiterated its $375m North America sales target by FY28.
Audio Recording of Earnings Call dated July 31, 2026, pertaining to unaudited financial results for Q1 FY27
Audio / Video · 01 Aug 2026, 1:02 am
Strides Pharma Q1 FY27 Earnings Call Recording Available Strides Pharma Science has published the audio recording of its earnings call held on 31 Jul'26. The call discussed the company's unaudited financial results for the first quarter ending 30 Jun'26. The recording is now accessible on the company's investor relations website for analysts and investors.
Earnings Presentation for the quarter ended June 30, 2026
Investor Presentation · 31 Jul 2026, 6:14 pm
Strides Q1FY27: Ex-US Markets Drive Revenue Growth Amid Margin Pressure Strides reported Q1FY27 revenue of ₹12,654m, up 13.0% YoY, driven by strong 17% growth in Ex-US markets. US revenue grew a modest 4% YoY to ₹6,282m. Consolidated EBITDA increased 5.4% YoY to ₹2,298m, but the EBITDA margin contracted by 130bps to 18.2% due to higher freight and operating costs. Operational PAT grew 8.0% to ₹1,231m. Reported PAT surged 56.7% YoY to ₹1,655m, boosted by a stake sale. Net Debt/EBITDA stood at a stable 1.52x as of Jun'26.
Strides Delivers Steady Performance with Q1FY27; Revenue at Rs. 12,654m, Grew 13% YoY; Ex-US Markets Grew 17% YoY
Press Release · 31 Jul 2026, 6:12 pm
Strides Pharma Q1FY27 Revenue Grows 13% YoY, Ex-US Markets Drive Performance Strides Pharma reported a steady Q1FY27 with revenue up 13% YoY to ₹12,654m for the quarter ended 30 Jun'26. Growth was led by a strong 17% YoY increase in Ex-US markets, while US business grew a modest 4% YoY. EBITDA rose 5.4% YoY to ₹2,298m, with the EBITDA margin contracting 130 bps to 18.2% due to a ₹131m impact from freight costs. Reported PAT surged 56.7% YoY to ₹1,655m, aided by the divestment of a majority stake in its captive GCC, Pivot Path.
Outcome of Board Meeting of the Company held on July 31, 2026
Financial Result · 31 Jul 2026, 6:07 pm
Strides Pharma Science Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) ■ Revenue: 12,654 (+13.0% YoY | -4.4% QoQ) ■ EBITDA: 2,298 (+5.4% YoY | -4.1% QoQ) ■ EBITDA Margin (%): 18.2 (-132 bps YoY | +5 bps QoQ) ■ PAT: 1,569 (+57.5% YoY | +23.6% QoQ) ■ EPS (INR): 17.0 (+57.4% YoY | +23.6% QoQ)
Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter ended June 30, 2026
Intimation · 31 Jul 2026, 5:00 pm
Strides Pharma Announces Q1FY27 Earnings Call for Jul 31, 2026 Strides Pharma Science has scheduled an earnings call for investors and analysts on Fri, 31st Jul'26, at 17:00 IST. The conference call will discuss the unaudited financial results for the quarter ending 30th Jun'26 (Q1FY27). Senior management, including Managing Director & Group CEO Badree Komandur and Group CFO Vikesh Kumar, will participate. The company has provided dial-in details for various regions, including India, the USA, UK, Singapore, and Hong Kong, for participation in the group meet.
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve the unaudited financial ....
Intimation · 31 Jul 2026, 5:30 am
Strides Pharma Board Meeting on Jul 31, '26 to Approve Q1 Results Strides Pharma Science has scheduled a Board of Directors meeting for Fri, Jul 31, '26. The agenda includes the consideration and approval of the company's unaudited standalone and consolidated financial results for the quarter ended Jun 30, '26. In compliance with insider trading regulations, the trading window for designated persons has been closed since Jul 1, '26, and will reopen 48 hours after the results are declared.
Business Responsibility and Sustainability Report for FY 2026
Others (Uncategorized) · 21 Jul 2026, 9:00 pm
Strides Pharma FY26 Business Responsibility & Sustainability Report Strides Pharma submitted its Business Responsibility & Sustainability Report for the year ended 31 Mar'26. On a standalone basis, exports contributed 90.66% to total turnover, with products marketed in 106 countries. FY26 turnover was ₹21,801.36 million with a net worth of ₹28,953.13 million. The permanent employee turnover rate increased to 20.8% from 18.7% in FY25. Related party transactions constituted 86.4% of sales and 22.9% of purchases. Key identified risks include product quality, geopolitical instability, and regulatory compliance. The company reported three voluntary product recalls.